000866389 000__ 05320cam\a2200505Ii\4500
000866389 001__ 866389
000866389 005__ 20230306145708.0
000866389 006__ m\\\\\o\\d\\\\\\\\
000866389 007__ cr\cn\nnnunnun
000866389 008__ 190329s2019\\\\sz\\\\\\ob\\\\001\0\eng\d
000866389 019__ $$a1090970413
000866389 020__ $$a9783030126681$$q(electronic book)
000866389 020__ $$a3030126684$$q(electronic book)
000866389 020__ $$z9783030126674
000866389 020__ $$z3030126676
000866389 035__ $$aSP(OCoLC)on1090813013
000866389 035__ $$aSP(OCoLC)1090813013$$z(OCoLC)1090970413
000866389 040__ $$aN$T$$beng$$erda$$epn$$cN$T$$dN$T$$dOCLCO$$dYDX$$dGW5XE$$dEBLCP
000866389 049__ $$aISEA
000866389 050_4 $$aRC627.54
000866389 08204 $$a616.3/9$$223
000866389 24500 $$aReviews on biomarker studies of metabolic and metabolism-related disorders /$$ceditor: Paul C. Guest.
000866389 264_1 $$aCham, Switzerland :$$bSpringer Nature,$$c[2019]
000866389 300__ $$a1 online resource.
000866389 336__ $$atext$$btxt$$2rdacontent
000866389 337__ $$acomputer$$bc$$2rdamedia
000866389 338__ $$aonline resource$$bcr$$2rdacarrier
000866389 4901_ $$aAdvances in experimental medicine and biology. Proteomics, metabolomics, interactomics and systems biology ;$$vv. 1134
000866389 504__ $$aIncludes bibliographical references and index.
000866389 5050_ $$aIntro; Preface; Contents; Contributors; Chapter 1: Insulin Resistance in Schizophrenia; 1.1 Introduction; 1.2 Insulin Resistance and Metabolic Syndrome Associated with Antipsychotic Treatment; 1.3 Insulin Resistance in First Onset Antipsychotic Naive Schizophrenia Patients; 1.4 Effects of Insulin Resistance in Schizophrenia on Other Neuroendocrine Systems; 1.4.1 Growth Hormone; 1.4.2 Cortisol; 1.4.3 Gonadal Steroids; 1.4.4 Other Hormones; 1.5 Conclusions; References; Chapter 2: Biogenesis of the Insulin Secretory Granule in Health and Disease; 2.1 Introduction; 2.2 Biosynthesis of Insulin
000866389 5058_ $$a2.3 Secretion of the Insulin Secretory Granule Contents2.4 Insulin Secretory Granule Contents; 2.4.1 Chromogranin A; 2.4.2 PC1; 2.4.3 PC2; 2.4.4 CPH; 2.4.5 Other Insulin Secretory Granule Proteins; 2.5 Conclusions; References; Chapter 3: Current Models of Fatty Liver Disease; New Insights, Therapeutic Targets and Interventions; 3.1 Introduction; 3.2 NASH Pathogenesis; 3.3 Diet-Induced Models; 3.3.1 High Fat Diet (HFD); 3.3.2 Modified High Fat Diets; 3.3.3 Methionine- and Choline-Deficient Diet (MCD); 3.4 Mechanistic Insights, Susceptibility Factorsand Interventions
000866389 5058_ $$a3.4.1 Mitochondrial Stress3.4.2 Oxidative Stress; 3.4.3 Inflammation; 3.4.4 Gut-Liver Axis and Microbiome; 3.5 Animal Models to Study Developmental Origins of NAFLD; 3.5.1 Rodents; 3.5.2 Non-human Primates; 3.5.3 Other Models; 3.6 Brain-Liver Axis; 3.7 Conclusions; References; Chapter 4: Preclinical Models of Altered Early Life Nutrition and Development of Reproductive Disorders in Female Offspring; 4.1 Introduction; 4.1.1 Developmental Origins of Health and Disease; 4.1.2 The Importance of Preclinical Models; 4.1.3 Metabolic Effects on Reproductive Health; 4.2 Study Design
000866389 5058_ $$a4.2.1 Animal Husbandry Guidelines4.2.2 Diets; 4.2.3 Preventing Bias; 4.2.4 Timing; 4.3 Animal Models; 4.3.1 Rodents; 4.3.2 Sheep; 4.3.3 Non-human Primates; 4.4 Models of Reproductive Dysfunction; 4.5 Early-Life Dietary Models and Reproductive Dysfunction; 4.5.1 Undernutrition; 4.5.1.1 Global Undernutrition; 4.5.1.2 Protein Restriction; 4.5.2 Maternal Overnutrition; 4.5.2.1 Single Source High-Fat Diet; 4.5.2.2 Other Single Nutrient Diets; 4.5.2.3 Cafeteria Diet; 4.5.3 Surgical Interventions; 4.6 Conclusions; References
000866389 506__ $$aAccess limited to authorized users.
000866389 520__ $$aThe book recognizes that throughout the scientific, medical, and economic communities, new tests incorporating biomarkers are needed to improve the diagnosis of patients suffering from metabolic disorders. The early identification of those at risk of developing obesity will help to place these individuals on the best treatment course as early as possible for improved treatment outcomes. This will also help to cut costs incurred by the healthcare services. For all of this to occur, new research efforts are needed to identify novel biomarkers that can be used to predict the disease in the presymptomatic stage, for disease monitoring and for prediction of treatment response. It is also possible that new drug targets can be identified using these approaches which, in turn, can lead to the development of new treatment approaches. This volume also includes a series of reviews on biomarker discovery and usage in the study of diseases marked by perturbations in metabolism. It will describe the pros and cons of the various approaches and cover the successes and failures in this important research field.
000866389 588__ $$aOnline resource; title from PDF title page (viewed April 1, 2019).
000866389 650_0 $$aMetabolism$$xDisorders$$xResearch.
000866389 650_0 $$aBiochemical markers$$xResearch.
000866389 7001_ $$aGuest, Paul C.,$$eeditor.
000866389 77608 $$iPrint version: $$z3030126676$$z9783030126674$$w(OCoLC)1082215914
000866389 830_0 $$aAdvances in experimental medicine and biology.$$pProteomics, metabolomics, interactomics and systems biology ;$$vv. 1134.
000866389 852__ $$bebk
000866389 85640 $$3SpringerLink$$uhttps://univsouthin.idm.oclc.org/login?url=http://link.springer.com/10.1007/978-3-030-12668-1$$zOnline Access$$91397441.1
000866389 909CO $$ooai:library.usi.edu:866389$$pGLOBAL_SET
000866389 980__ $$aEBOOK
000866389 980__ $$aBIB
000866389 982__ $$aEbook
000866389 983__ $$aOnline
000866389 994__ $$a92$$bISE